ABSTRACT NUMBER: ESOC2026A2331 PRECISION STROKE SECONDARY PREVENTION USING CYP2C19 GENOTYPE POINT-OF-CARE TESTING

Radim Licenik, Charlotte Murray, Mohammad Haque, Mmua Ngwako, Suleman Mohammed, Mohsen Kermani, Silvie Davis, Dipraj Limbu, Martin Huncovsky · 2026

Read ABSTRACT NUMBER: ESOC2026A2331 PRECISION STROKE SECONDARY PREVENTION USING CYP2C19 GENOTYPE POINT-OF-CARE TESTING by Radim Licenik, Charlotte Murray, Mohammad Haque, Mmua Ngwako, Suleman Mohammed, Mohsen Kermani, Silvie Davis, Dipraj Limbu, Martin Huncovsky (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13144915.txt.

Description

Radim Licenik and co-authors report bedside genetic testing after stroke in a 2026 conference abstract. The standard preventive drug clopidogrel fails in over a quarter of people because a liver enzyme variant, in the CYP2C19 gene, cannot activate it properly, leaving them exposed to another stroke.

A point-of-care test checked the six commonest variants in selected patients: the young, those with repeat events, and those who had clot-removal treatment. Results sorted patients from poor to ultra-rapid metabolizers, and a multidisciplinary team adjusted each prescription. The abstract presents the rollout, run over most of a year, as precision prevention in action.

Catalog record

CREATORRadim Licenik, Charlotte Murray, Mohammad Haque, Mmua Ngwako, Suleman Mohammed, Mohsen Kermani, Silvie Davis, Dipraj Limbu, Martin Huncovsky
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE2 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC13144915

Browse the full library · About the Tower of Babel